Evidence map›Paper›PMID 42395167›Full record

ArticleWorld journal of nuclear medicine2026

Optimization of Administered Activity for

Eva Lengyelova, Manisha Patel, Glynn Morrish, Erik Mittra, Alessandra Malaroda, Othon Gervasio, Thomas Armor

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04839367 (Positron Emission Tomography Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04839367 phase1completednot on this map

Positron Emission Tomography Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: A Multi-Centre, Blinded Review, Dose Ranging Phase I Study

TypeinterventionalSponsorClarity Pharmaceuticals LtdRan2021 to 2022Enrolled30ConditionsProstatic NeoplasmsArms64Cu-SAR-bisPSMA
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Uneven Global Distribution of Theranostics.World journal of nuclear medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eva LengyelovaClarity Pharmaceuticals, Sydney, Australia.
Manisha PatelClarity Pharmaceuticals, Sydney, Australia.
Glynn MorrishClarity Pharmaceuticals, Sydney, Australia.
Erik MittraDivision of Molecular Imaging and Therapy, Oregon Health & Science University, Portland, Oregon, United States.
Alessandra MalarodaNuclear Medicine and PET Department, Nepean Hospital, Kingswood, Australia.ORCID 0000-0003-2127-146X
Othon GervasioClarity Pharmaceuticals, Sydney, Australia.
Thomas ArmorClarity Pharmaceuticals, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: The PROPELLER trial (CLP03; NCT04839367) enrolled 30 men with untreated, histopathology-confirmed, primary PC with intermediate- to high-risk features. Participants received an intravenous injection of Results: Mean Image Utility Classification Score was the highest in the 200 MBq Conclusions: An AA of 200 MBq was identified as the optimal AA for

Indexed as

64 Cu-SAR-bisPSMAdiagnosisPET/CTprostate cancerPSMA

Identifiers

PMID42395167
PMCPMC13327745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.